These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

946 related articles for article (PubMed ID: 25744474)

  • 1. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
    Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
    Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M; Bénard É; Pérez N; Brisson M;
    Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
    Lehtinen M; Apter D
    Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
    Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
    Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
    Garland SM; Kjaer SK; Muñoz N; Block SL; Brown DR; DiNubile MJ; Lindsay BR; Kuter BJ; Perez G; Dominiak-Felden G; Saah AJ; Drury R; Das R; Velicer C
    Clin Infect Dis; 2016 Aug; 63(4):519-27. PubMed ID: 27230391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
    Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
    BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
    BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances.
    Goodman E; Reuschenbach M; Viering T; Luzak A; Greiner W; Hampl M; Jacob C
    Arch Gynecol Obstet; 2024 Nov; 310(5):2639-2646. PubMed ID: 39230793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
    Sharma M; Sy S; Kim JJ
    BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
    Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
    Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Papillomavirus Vaccination and Anogenital Warts: A Systematic Review of Impact and Effectiveness in the United States.
    Yakely AE; Avni-Singer L; Oliveira CR; Niccolai LM
    Sex Transm Dis; 2019 Apr; 46(4):213-220. PubMed ID: 30461595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
    Osmani V; Fett S; Tauscher M; Donnachie E; Schneider A; Klug SJ
    BMC Cancer; 2022 Dec; 22(1):1293. PubMed ID: 36494790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
    Kim JJ
    Lancet Infect Dis; 2010 Dec; 10(12):845-52. PubMed ID: 21051295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the long-term effects of HPV vaccination in Germany.
    Horn J; Damm O; Kretzschmar ME; Deleré Y; Wichmann O; Kaufmann AM; Garbe E; Krämer A; Greiner W; Mikolajczyk RT
    Vaccine; 2013 May; 31(19):2372-80. PubMed ID: 23518405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis.
    Lukács A; Máté Z; Farkas N; Mikó A; Tenk J; Hegyi P; Németh B; Czumbel LM; Wuttapon S; Kiss I; Gyöngyi Z; Varga G; Rumbus Z; Szabó A
    BMC Public Health; 2020 May; 20(1):691. PubMed ID: 32460747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.